Drug developer Tesaro explores sale
New Delhi: Cancer Drug Developer Tesaro Inc is exploring a sale and is working with financial advisers after receiving takeover interest, Bloomberg reported on Friday, citing people familiar with the matter.
Shares of the Waltham, Massachusetts-based company rose as much as 44 per cent on the news in regular trading.
The company, which has a market capitalization of $1.92 billion, said it does not comment on rumour or speculation.
According to the Bloomberg report, the advisers have begun contacting other potential suitors and the company could opt to remain independent.
Tesaro has received acquisition interest from several drugmakers in the past. In July, reports emerged of a possible buyout of the company by Swiss drugmaker RocheHolding AG.
Tesaro's lead ovarian cancer drug, Zejula, competes with Clovis Oncology Inc's Rubraca and AstraZeneca's Lynparza - all of which belong to a closely watched class of new medicines called PARP inhibitors.
Clovis Oncology Incfinancial advisersLynparzaMassachusettsPARP inhibitorsRocheTesaro IncWalthamZejula
Source : ReutersMedical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Next Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd